| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_03ead6aa4335a77a8b9989045549202c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1d7e470e09803bd6bf24b2fd176109dd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1a6b4356e1de163952f93b3523da980d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-357
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7036 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-357
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7036
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7052 |
| filingDate |
2010-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f1b8e11d4c65c1b766e4d4146f48233
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ddbfd0aabb7c4e6aab5b9a1e1ce2414e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_863f184478a38b8b920395e3c414b4cc |
| publicationDate |
2012-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20120004448-A |
| titleOfInvention |
Gram-negative bacteria removal composition and method |
| abstract |
Oral drug delivery formulations are disclosed which specifically administer an antibacterial agent to the ileum, caecum and / or colon and do not significantly administer to other sites of the gastrointestinal tract. The formulation includes a combination of macrolide or aminoglycoside or quinolone antibacterial agent as an active agent and an anti-gram negative lipopeptide (polymyxin) antibacterial agent or other peptide antibacterial agent effective against Gram negative bacteria. The formulations can be used to treat infections or unwanted bacterial habitats in the colon and can effectively decontaminate the flora of the colon from unwanted or potentially pathogenic bacteria. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2668160-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20160118994-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016159741-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10792340-B2 |
| priorityDate |
2009-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |